Literature DB >> 28685537

Effect of Xianling Gubao capsules on bone mineral density in osteoporosis patients.

Z H Wu1, X Zhu1, C K Xu1, Y J Chen1, L Zhang1, C L Zhang1.   

Abstract

This paper aimed to analyze the clinical effects of Xianling Gubao capsules on the bone mineral density (BMD) of 94 patients with osteoporosis. After reviewing and analyzing the clinical information in our hospital from January 2015 to January 2016, the patients were divided into a control group and a treatment group with 47 cases in each group. Patients in the control group were treated with routine Western medicine, while the treatment group received Xianling Gubao capsules. Both groups were treated continuously for 3 courses (30 days each course) and had their BMD analyzed and compared. The effective rates of the treatment group and control group were 91.48% and 70.21%, respectively, with statistical significance (P less than 0.05). Compared with the same group before the treatment, the bone metabolic indexes (blood calcium, phosphorus, and alkaline phosphate) and the BMD of the femoral neck and lumbar vertebrae (L1-2, L3-4, L2-4) of both groups were all improved with statistical significance (P less than 0.05) after the treatment. The above indexes of the treatment group were all significantly higher than those of the control group, with statistical significance (P less than 0.05). Compared with the same group before treatment (P less than 0.05), the osteocalcin (OC) levels of both groups were increased, and the Cross-linked N-telopeptide of type 1 collagen (CTX-1) levels were decreased after the treatment. The OC level in the treatment group was higher when compared with the control group, while the CTX-1 level was lower compared to the control group (P less than 0.05). Moreover, no significant side-effects or adverse events were observed during the treatment and observation period. The Xianling Gubao Capsule possesses a therapeutic effect for BMD in osteoporosis patients, which can effectively increase their BMD, improve their bone metabolism, and control the loss of bone mass, therefore, can be used in clinical promotion and application.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28685537

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  6 in total

1.  Exploring the Pharmacological Mechanism of Duhuo Jisheng Decoction in Treating Osteoporosis Based on Network Pharmacology.

Authors:  Zhencheng Xiong; Can Zheng; Yanan Chang; Kuankuan Liu; Li Shu; Chi Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-05       Impact factor: 2.629

2.  A Traditional Chinese Medicine Plant Extract Prevents Alcohol-Induced Osteopenia.

Authors:  Dongyang Qian; Hui Zhou; Pan Fan; Tao Yu; Anish Patel; Morgan O'Brien; Zhe Wang; Shiguang Lu; Guoqiang Tong; Yimin Shan; Lei Wang; Yuan Gao; Yuan Xiong; Lily Zhang; Xin Wang; Yuancai Liu; Shuanhu Zhou
Journal:  Front Pharmacol       Date:  2021-12-15       Impact factor: 5.810

3.  Uncovering Hidden Mechanisms of Different Prescriptions Treatment for Osteoporosis via Novel Bioinformatics Model and Experiment Validation.

Authors:  Yujie Liu; Qinwen Liu; Chuanhui Yin; Yi Li; Jie Wu; Quanlin Chen; Hailang Yu; Aiping Lu; Daogang Guan
Journal:  Front Cell Dev Biol       Date:  2022-02-08

4.  Combined Therapy of Yishen Zhuanggu Decoction and Caltrate D600 Alleviates Postmenopausal Osteoporosis by Targeting FoxO3a and Activating the Wnt/β-Catenin Pathway.

Authors:  Bole Li; Changqing Jiang; Xinyu Zhan
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-15       Impact factor: 2.650

5.  Identification of kaempferol as an OSX upregulator by network pharmacology-based analysis of qianggu Capsule for osteoporosis.

Authors:  Ann Yehong Huang; Zhencheng Xiong; Kuankuan Liu; Yanan Chang; Li Shu; Guolan Gao; Chi Zhang
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

6.  Chinese herbal medicine Xianling Gubao capsule for knee osteoarthritis: A protocol for systematic review and meta-analysis.

Authors:  Wang Liu; Daoqing Xu; Qi Qi; Jingjing Li; Liang Ou
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.